This year’s fair competition among statin/ezetimibe complexes

Fierce competition is expected among complex drugs owning the strong function of inhibiting cholesterol with the combination of statin and ezetimibe.

In particular, the three-way fight – Chong Kun Dang which acquired the sale right of the selected drug, ‘Vytorin,’ Daewoong Pharmaceutical that reversely lost the right and Hanmi Pharm which entered the market with its patent license at the end o...